Skip to main content
Premium Trial:

Request an Annual Quote

Kevin Fitzpatrick

Kevin Fitzpatrick has been named CEO of CancerLinQ, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology. 

Fitzpatrick will begin his new role on August 3. In the position, he will be responsible for driving the mission, operations, and ensuring the financial sustainability of CancerLinQ, an SAP HANA-based platform for processing and analyzing data from electronic health records.

Fitzpatrick is currently the executive vice president and chief innovation officer of the American College of Cardiology. Prior to that, he was vice president of business development for Lippincott Williams & Wilkins, a publisher of professional health information resources, managing director of the Duke/Hewlett Packard Center for Outcomes Research, and director of the Trauma Research Laboratory at Duke University Medical Center.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.